$OPK
OPKO HEALTH, INC. Stock $opk

$opk Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000094480921000058 Filed on October 28, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$401.3M	$385.8M	$494.7M
YoY Change	-18.87%	-9.87%	120.5%
Cost Of Revenue	$292.8M	$244.0M	$318.7M
YoY Change	-8.12%	-10.57%	123.96%
Gross Profit	$108.5M	$141.9M	$175.9M
YoY Change	-38.31%	-8.66%	114.25%
Gross Profit Margin	27.04%	36.77%	35.56%
Selling, General & Admin	$138.2M	$105.1M	$101.8M
YoY Change	35.77%	5.23%	28.7%
% of Gross Profit	127.38%	74.1%	57.87%
Research & Development	$21.01M	$18.31M	$17.50M
YoY Change	20.04%	-1.01%	-23.91%
% of Gross Profit	19.36%	12.9%	9.95%
Depreciation & Amortization	$19.19M	$18.96M	$20.10M
YoY Change	-4.52%	-9.85%	-10.67%
% of Gross Profit	17.69%	13.37%	11.43%
Operating Expenses	$464.4M	$348.0M	$445.3M
YoY Change	4.29%	-14.32%	32.22%
Operating Profit	-$355.9M	$37.83M	-$269.4M
YoY Change	32.1%	72.41%	5.78%
Interest Expense	-$4.026M	-$2.998M	-$5.500M
YoY Change	-26.8%	-50.03%	7.84%
% of Operating Profit		-7.93%
Other Income/Expense, Net	$1.297M	-$6.354M	$2.100M
YoY Change	-38.24%	392.56%	-76.92%
Pretax Income	-$65.81M	$31.47M	$45.90M
YoY Change	-243.38%	52.41%	-142.34%
Income Tax	$7.496M	$2.680M	$13.60M
% Of Pretax Income		8.52%	29.63%
Net Earnings	-$73.77M	$28.74M	$32.30M
YoY Change	-328.42%	21.17%	-128.75%
Net Earnings / Revenue	-18.38%	7.45%	6.53%
Basic Earnings Per Share	-$0.11	$0.04	$0.05
Diluted Earnings Per Share	-$0.11	$0.04	$0.05
COMMON SHARES
Basic Shares Outstanding	681.3M shares	651.8M shares	670.0M shares
Diluted Shares Outstanding		651.8M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$134.7M	$148.6M	$72.20M
YoY Change	86.58%	309.36%	-15.56%
Cash & Equivalents	$134.7M	$148.6M	$72.21M
Short-Term Investments
Other Short-Term Assets	$6.195M	$11.00M	$5.309M
YoY Change	16.69%	45.89%	-66.48%
Inventory	$86.50M	$112.9M	$132.3M
Prepaid Expenses
Receivables	$259.6M	$255.2M	$286.3M
Other Receivables	$5.951M	$10.33M	$16.00M
Total Short-Term Assets	$823.0M	$557.5M	$523.2M
YoY Change	57.31%	30.23%	61.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$124.0M	$141.0M	$140.6M
YoY Change	-11.81%	5.15%	10.58%
Goodwill	$520.6M	$674.6M	$680.6M
YoY Change	-23.51%	-0.18%	1.29%
Intangibles
YoY Change
Long-Term Investments	$10.73M	$11.75M	$15.70M
YoY Change	-31.66%	-17.81%	-23.79%
Other Assets	$9.534M	$8.744M	$10.06M
YoY Change	-5.23%	49.29%	46.05%
Total Long-Term Assets	$1.577B	$1.860B	$1.950B
YoY Change	-19.14%	-4.27%	-1.78%
TOTAL ASSETS
Total Short-Term Assets	$823.0M	$557.5M	$523.2M
Total Long-Term Assets	$1.577B	$1.860B	$1.950B
Total Assets	$2.400B	$2.418B	$2.473B
YoY Change	-2.97%	1.95%	7.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$82.04M	$94.39M	$100.9M
YoY Change	-18.68%	43.71%	61.32%
Accrued Expenses	$193.5M	$163.9M	$240.9M
YoY Change	-19.67%	-34.01%	46.05%
Deferred Revenue	$258.0K	$3.004M	$15.78M
YoY Change	-98.37%	-78.69%	-17.78%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$16.95M	$16.70M	$27.20M
YoY Change	-37.68%	11.35%	119.35%
Total Short-Term Liabilities	$330.0M	$283.0M	$375.5M
YoY Change	-12.11%	-15.74%	50.72%
LONG-TERM LIABILITIES
Long-Term Debt	$193.1M	$1.671M	$3.837M
YoY Change	4932.13%	-58.33%	-1.77%
Other Long-Term Liabilities	$15.06M	$20.99M	$37.07M
YoY Change	-59.37%	-53.39%	-57.78%
Total Long-Term Liabilities	$384.6M	$369.0M	$426.0M
YoY Change	-9.73%	-10.35%	-4.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$330.0M	$283.0M	$375.5M
Total Long-Term Liabilities	$384.6M	$369.0M	$426.0M
Total Liabilities	$714.6M	$652.1M	$801.5M
YoY Change	-10.84%	-12.77%	15.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.512B	-$1.438B	-$1.482B
YoY Change	2.03%	-5.01%	-1.94%
Common Stock	$6.901M	$6.900M	$6.706M
YoY Change	2.91%	2.89%	0.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.791M	$1.791M	$1.791M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	8.655M shares	8.655M shares	549.9K shares
Shareholders Equity	$1.685B	$1.766B	$1.672B
YoY Change
Total Liabilities & Shareholders Equity	$2.400B	$2.418B	$2.473B
YoY Change	-2.97%	1.95%	7.09%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$73.77M	$28.74M	$32.30M
YoY Change	-328.42%	21.17%	-128.75%
Depreciation, Depletion And Amortization	$19.19M	$18.96M	$20.10M
YoY Change	-4.52%	-9.85%	-10.67%
Cash From Operating Activities	-$5.643M	$33.40M	$34.30M
YoY Change	-116.45%	-46.99%	-174.57%
INVESTING ACTIVITIES
Capital Expenditures	-$6.730M	-$7.234M	-$6.800M
YoY Change	-1.03%	-26.18%	78.95%
Acquisitions
YoY Change
Other Investing Activities	-$1.949M	$61.81M	$100.0K
YoY Change	-2049.0%	306.64%	0.0%
Cash From Investing Activities	-$8.679M	$54.58M	-$6.700M
YoY Change	29.54%	892.29%	76.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	832.0K	-4.256M	8.100M
YoY Change	-89.73%	-92.19%	-88.53%
NET CHANGE
Cash From Operating Activities	-5.643M	33.40M	34.30M
Cash From Investing Activities	-8.679M	54.58M	-6.700M
Cash From Financing Activities	832.0K	-4.256M	8.100M
Net Change In Cash	-13.49M	83.72M	35.70M
YoY Change	-137.79%	497.97%	71.63%
FREE CASH FLOW
Cash From Operating Activities	-$5.643M	$33.40M	$34.30M
Capital Expenditures	-$6.730M	-$7.234M	-$6.800M
Free Cash Flow	$1.087M	$40.63M	$41.10M
YoY Change	-97.36%	-44.19%	-197.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000944809
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member
CY2021Q3	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33528
	dei	Entity Registrant Name EntityRegistrantName	OPKO Health, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-2402409
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4400 Biscayne Blvd.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33137
	dei	City Area Code CityAreaCode	(305)
	dei	Local Phone Number LocalPhoneNumber	575-4100
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	OPK
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	681341306	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148599000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72211000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	255192000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	286314000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	112861000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	132341000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40858000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32313000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	557510000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	523179000	USD
CY2021Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	107500000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	140554000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	433855000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	475002000	USD
CY2021Q3	opk	In Process Researchand Development InProcessResearchandDevelopment	590200000	USD
CY2020Q4	opk	In Process Researchand Development InProcessResearchandDevelopment	590200000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	674574000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	680602000	USD
CY2021Q3	us-gaap	Long Term Investments LongTermInvestments	11753000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	15731000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33502000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	37735000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8744000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10060000	USD
CY2021Q3	us-gaap	Assets Assets	2417638000	USD
CY2020Q4	us-gaap	Assets Assets	2473063000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	94393000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	100883000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	163926000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	240869000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9823000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9028000	USD
CY2021Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	14893000	USD
CY2020Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	24703000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	283035000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	375483000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28256000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29760000	USD
CY2021Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	185543000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	221989000	USD
CY2021Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	134247000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	137208000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20990000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37072000	USD
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	369036000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	426029000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	652071000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	801512000	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	689996658	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	670585576	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	6900000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	6706000	USD
CY2021Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	8655082	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	549907	shares
CY2021Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1791000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1791000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3218583000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3152694000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-19923000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4225000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1438202000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1481833000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1765567000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1671551000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2417638000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2473063000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	385813000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	428064000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1373387000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	940739000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	105120000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	99897000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	330643000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	253749000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18306000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18493000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55843000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57862000	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-497000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1083000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1556000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1334000	USD
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12609000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13879000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37760000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43753000	USD
CY2021Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	31508000	USD
CY2020Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	31508000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	347987000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	406125000	USD
	us-gaap	Operating Expenses OperatingExpenses	1291553000	USD
	us-gaap	Operating Expenses OperatingExpenses	932381000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	37826000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	21939000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	81834000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	8358000	USD
CY2021Q3	opk	Interest Income Nonoperating InterestIncomeNonoperating	9000	USD
CY2020Q3	opk	Interest Income Nonoperating InterestIncomeNonoperating	1000	USD
	opk	Interest Income Nonoperating InterestIncomeNonoperating	21000	USD
	opk	Interest Income Nonoperating InterestIncomeNonoperating	149000	USD
CY2021Q3	opk	Interest Expense Nonoperating InterestExpenseNonoperating	4290000	USD
CY2020Q3	opk	Interest Expense Nonoperating InterestExpenseNonoperating	5544000	USD
	opk	Interest Expense Nonoperating InterestExpenseNonoperating	14572000	USD
	opk	Interest Expense Nonoperating InterestExpenseNonoperating	16514000	USD
CY2021Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	1283000	USD
CY2020Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-496000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	571000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	112000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3356000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4749000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16067000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10637000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6354000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1290000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30047000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5616000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	31472000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	20649000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	51787000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2742000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2680000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3178000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7993000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4021000	USD
CY2021Q3	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	28792000	USD
CY2020Q3	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	23827000	USD
	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	43794000	USD
	opk	Income Lossfrom Continuing Operations Before Investmentsin Investees Extraordinary Items Noncontrolling Interest Netof Tax IncomeLossfromContinuingOperationsBeforeInvestmentsinInvesteesExtraordinaryItemsNoncontrollingInterestNetofTax	-1279000	USD
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-53000	USD
CY2020Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-110000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-163000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-433000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	28739000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	23717000	USD
	us-gaap	Net Income Loss NetIncomeLoss	43631000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1712000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	651843074	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	651843074	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	640699982	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	640699982	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	646710240	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	646710240	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	640619485	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	640619485	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	28739000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	23717000	USD
	us-gaap	Net Income Loss NetIncomeLoss	43631000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1712000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9991000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	8301000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-15698000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	4619000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	18748000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	32018000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	27933000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2907000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1742585000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3822000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	412000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	28739000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9991000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1765567000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1671551000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9929000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	879000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	55275000	USD
	us-gaap	Net Income Loss NetIncomeLoss	43631000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15698000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1765567000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1588343000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2740000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	669000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	23717000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	8301000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1623770000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1614759000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6777000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	669000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1712000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4619000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1623770000	USD
	us-gaap	Net Income Loss NetIncomeLoss	43631000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1712000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	59525000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	65295000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	7164000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	7639000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	603000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	626000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-163000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-433000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9929000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6777000	USD
	opk	Non Cash Revenue From Transfer Of Intellectual Property NonCashRevenueFromTransferOfIntellectualProperty	3801000	USD
	opk	Non Cash Revenue From Transfer Of Intellectual Property NonCashRevenueFromTransferOfIntellectualProperty	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	35484000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	10172000	USD
	opk	Gain Loss On Conversion Of Debt GainLossOnConversionOfDebt	-11111000	USD
	opk	Gain Loss On Conversion Of Debt GainLossOnConversionOfDebt	0	USD
	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	-1919000	USD
	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	-1253000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1556000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1334000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2378000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1974000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-27934000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	107255000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-14254000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	60565000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13738000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13111000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1015000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	270000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4746000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3261000	USD
	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	2382000	USD
	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	-782000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-13016000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4717000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-65687000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	88988000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	43980000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5218000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	8079000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	15110000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	65975000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	192000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	25426000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	26885000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	44628000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11583000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	188000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	879000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	669000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1326641000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	699079000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	68775000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1338515000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	742932000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11183000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-43184000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1037000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	391000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	76388000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49158000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72211000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85452000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148599000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36294000	USD
	us-gaap	Interest Paid Net InterestPaidNet	8386000	USD
	us-gaap	Interest Paid Net InterestPaidNet	10657000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5509000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	148000	USD
	us-gaap	Depreciation Depreciation	21500000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	opk	Numberof Sales Employees NumberofSalesEmployees	300	employee
CY2021Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	31500000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.</span>
CY2021Q3	us-gaap	Inventory Write Down InventoryWriteDown	1300000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	5300000	USD
CY2020Q3	us-gaap	Inventory Write Down InventoryWriteDown	1700000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	3400000	USD
CY2020Q4	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1700000000	USD
CY2021Q3	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1700000000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	674600000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	680600000	USD
CY2021Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1000000000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1100000000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37800000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43800000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	6400000	USD
	us-gaap	Depreciation Depreciation	21800000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	7200000	USD
CY2021Q3	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	178687	shares
CY2021Q3	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	178687	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of credit risk and allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span>While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2300000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2100000	USD
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	600000	USD
CY2020Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	300000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3800000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9900000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2700000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6800000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	178687	shares
CY2021Q3	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	358812	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	358812	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	358812	shares
	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
CY2020Q3	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	171500	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	171500	shares
CY2020Q3	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	171500	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	171500	shares
CY2020Q3	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	171500	shares
	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	171500	shares
CY2020Q3	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
CY2021Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	257512000	USD
CY2020Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	288369000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2320000	USD
CY2020Q4	opk	Taxes Recoverable Current TaxesRecoverableCurrent	13440000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2055000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	255192000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	286314000	USD
CY2021Q3	us-gaap	Other Inventory Supplies OtherInventorySupplies	67978000	USD
CY2020Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	86779000	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	40642000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	36831000	USD
CY2021Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2768000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5268000	USD
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	6161000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5784000	USD
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4688000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2321000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	112861000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	132341000	USD
CY2021Q3	opk	Taxes Recoverable Current TaxesRecoverableCurrent	9680000	USD
CY2021Q3	us-gaap	Supplies Supplies	11890000	USD
CY2020Q4	us-gaap	Supplies Supplies	7259000	USD
CY2021Q3	us-gaap	Prepaid Insurance PrepaidInsurance	7630000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3803000	USD
CY2021Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	655000	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2502000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	11003000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5309000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40858000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32313000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	387861000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	356830000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	433855000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	475002000	USD
CY2021Q3	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	30053000	USD
CY2020Q4	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	72160000	USD
CY2021Q3	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	20141000	USD
CY2020Q4	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	15454000	USD
CY2021Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	43242000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	43300000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3004000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15783000	USD
CY2021Q3	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	4993000	USD
CY2020Q4	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	7112000	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	487000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1188000	USD
CY2021Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1809000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2453000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4889000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4985000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	55308000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	78434000	USD
CY2021Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	38023000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	163926000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	240869000	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2498000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4507000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1671000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3837000	USD
CY2021Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2302000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2805000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	357000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	595000	USD
CY2021Q3	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	14162000	USD
CY2020Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	25328000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20990000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37072000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	718625000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-6028000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	674574000	USD
CY2021Q3	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	727000	USD
CY2021Q3	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	9055000	USD
CY2020Q4	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	426000	USD
CY2020Q4	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	2252000	USD
CY2021Q3	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	1023000	USD
CY2021Q3	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	0	USD
CY2020Q4	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	1060000	USD
CY2020Q4	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	9000	USD
CY2021Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	6548000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	14136000	USD
CY2021Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	3409000	USD
CY2020Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	35000	USD
CY2021Q3	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	46000	USD
CY2020Q4	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	74000	USD
CY2021Q3	us-gaap	Long Term Investments LongTermInvestments	11753000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	15731000	USD
CY2021Q3	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	6300000	USD
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	491000	USD
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	8959000	USD
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-2981000	USD
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	10324000	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-2490000	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-1365000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	202587000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	251205000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	202587000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	251205000	USD
CY2021Q3	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	11	institution
CY2020Q4	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	11	institution
CY2021Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	103771000	USD
CY2021Q3	us-gaap	Line Of Credit LineOfCredit	14064000	USD
CY2020Q4	us-gaap	Line Of Credit LineOfCredit	22954000	USD
CY2021Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	6548000	USD
CY2021Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	7278000	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2985000	USD
CY2021Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2985000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	14136000	USD
CY2020Q4	us-gaap	Derivative Assets DerivativeAssets	74000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	14210000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	5695000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6735000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1700000	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3000000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	5700000	USD
CY2021Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	43000	USD
CY2020Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	62000	USD
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	156000	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3000000	USD
CY2021Q3	us-gaap	Purchase Obligation PurchaseObligation	223700000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	36000000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	1600000	USD
CY2021Q3	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	10600000	USD
CY2020Q4	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	14900000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16378000	USD
CY2021Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3362000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	13016000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	37826000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	21939000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	81834000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	8358000	USD
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18963000	USD
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21036000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	59525000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	65295000	USD
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-53000	USD
CY2020Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-110000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-163000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-433000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	385813000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	428064000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1373387000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	940739000	USD
CY2021Q3	us-gaap	Assets Assets	2417638000	USD
CY2020Q4	us-gaap	Assets Assets	2473063000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	674574000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	13400000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	680602000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33502000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	37735000	USD
CY2021Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	4111000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	5258000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9823000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9028000	USD
CY2021Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1809000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2453000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28256000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29760000	USD
CY2021Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2302000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2805000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M24D
CY2021Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.056
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2021Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.062
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.036
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1454000	USD
CY2021Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	671000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	11254000	USD
CY2021Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1658000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7939000	USD
CY2021Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	1063000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5749000	USD
CY2021Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	723000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3726000	USD
CY2021Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	247000	USD
CY2021Q3	opk	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	16361000	USD
CY2021Q3	opk	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	4000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46483000	USD
CY2021Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	4366000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8404000	USD
CY2021Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	255000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	38079000	USD
CY2021Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	4111000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	1400000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	13700000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2300000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	2300000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	12278000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	13596000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	101000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	149000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1498000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2009000	USD
	opk	Payments For Leases PaymentsForLeases	13877000	USD
	opk	Payments For Leases PaymentsForLeases	15754000	USD

Files In Submission

Name	View Source	Status
0000944809-21-000058-index-headers.html	Edgar Link	pending
0000944809-21-000058-index.html	Edgar Link	pending
0000944809-21-000058.txt	Edgar Link	pending
0000944809-21-000058-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opk-20210930.htm	Edgar Link	pending
opk-20210930.xsd	Edgar Link	pending
opk-20210930_cal.xml	Edgar Link	unprocessable
opk-20210930_def.xml	Edgar Link	unprocessable
opk-20210930_htm.xml	Edgar Link	completed
opk-20210930_lab.xml	Edgar Link	unprocessable
opk-20210930_pre.xml	Edgar Link	unprocessable
opk-9302021xex311.htm	Edgar Link	pending
opk-9302021xex312.htm	Edgar Link	pending
opk-9302021xex321.htm	Edgar Link	pending
opk-9302021xex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPK
OPKO HEALTH, INC. Stock $opk

2021 Q4 Form 10-Q Financial Statement

#000094480921000058 Filed on October 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK OPKO HEALTH, INC. Stock $opk

2021 Q4 Form 10-Q Financial Statement

#000094480921000058 Filed on October 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK
OPKO HEALTH, INC. Stock $opk